Intra-Cellular Therapies Inc. diskutieren
Intra-Cellular Therapies Inc.
WKN: A1XDTL / Symbol: ITCI / Name: ITI / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
66,00 €
-0,76 %
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $101.00 price target on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $86.00 price target on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $82.00 price target on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at TD Cowen from $80.00 to $90.00. They now have a "buy" rating on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Robert W. Baird from $83.00 to $103.00. They now have an "outperform" rating on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Bank of America Co. from $82.00 to $91.00. They now have a "buy" rating on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Mizuho from $82.00 to $96.00. They now have a "buy" rating on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Needham & Company LLC from $82.00 to $90.00. They now have a "buy" rating on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $120.00 price target on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $90.00 price target on the stock.
Ratings data for ITCI provided by MarketBeat
Buy Intra-Cellular Therapies Inc.
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at JPMorgan Chase & Co. from $75.00 to $78.00. They now have an "overweight" rating on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $120.00 price target on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Needham & Company LLC from $90.00 to $94.00. They now have a "buy" rating on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Mizuho from $96.00 to $100.00. They now have a "buy" rating on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $103.00 price target on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Needham & Company LLC from $94.00 to $100.00. They now have a "buy" rating on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Cantor Fitzgerald from $120.00 to $130.00. They now have an "overweight" rating on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target lowered by analysts at Royal Bank of Canada from $107.00 to $106.00. They now have an "outperform" rating on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at JPMorgan Chase & Co. from $79.00 to $81.00. They now have an "overweight" rating on the stock.
Ratings data for ITCI provided by MarketBeat
Neueste Beiträge
Macquarie in Brookdale Sr Lvg diskutieren